Ann Lab Med.  2020 Sep;40(5):417-420. 10.3343/alm.2020.40.5.417.

A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma

• Choi H
• Cho Sr
• Yang D
• Lee W
• Hwang H
• Lee HS
• Kim DJ
• Kim T
• Kim MH

• KMID: 2502573
• DOI: http://doi.org/10.3343/alm.2020.40.5.417

Figure

• 

  Fig. 1 Patient’s clinical features. (A) The karyotype analysis showed 46,XY,t(9;22)(q34;q11.2) in 15 of 20 cells evaluated (arrow). (B) The FISH study revealed fusion of ABL1 and BCR genes in 76.5% of interphase.

Reference

1. Gale RP, Hlatky L, Sachs RK, Radivoyevitch T. Why is there so much therapy-related AML and MDS and so little therapy-related CML? Leuk Res. 2014; 38:1162–4.

2. Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998; 29:17–26.

3. Lee HY, Lee KH, Hyun MS, Kim MK, Koh SA, Cho HS. Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma. Korean J Intern Med. 2014; 29:250–2.

4. Waller CF, Fetscher S, Lange W. Treatment-related chronic myelogenous leukemia. Ann Hematol. 1999; 78:341–54.

5. Millett R, Aggarwal A, Tabbara I, Nassereddine S. Chronic myeloid leukemia as secondary malignancy following the treatment of Hodgkin lymphoma: a case series. Anticancer Res. 2019; 39:4333–5.

6. Gheith S, Spranklin L, Agostino N. The clinical relevance of detection of BCR-ABL in an asymptomatic patient: a case report and review of the literature. Ann Clin Pathol. 2015; 3:1054.

7. Aye Le L, Loghavi S, Young KH, Siddiqi I, Yin CC, Routbort MJ, et al. Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. Ann Diagn Pathol. 2016; 21:53–8.

8. Yoo DW, Park SH, Yi J, Kim IS, Kim HH, Chang CL, et al. Hidden “preleukemic phase” of chronic myeloid leukemia presenting without leukocytosis in the peripheral blood unrelated to chemotherapy in a patient diagnosed with diffuse large B cell lymphoma. Ann Lab Med. 2017; 37:443–5.

9. Berman E, Strife A, Wisniewski D, Desai S, Gulati S, Jhanwar S, et al. Duration of the preclinical phase of chronic myelogenous leukemia: a case report. Blood. 1991; 78:2969–72.

10. Bolaños-Meade J, Sarkodee-Adoo C, Khanwani SL. CML after treatment for lymphoid malignancy: therapy-related CML or coincidence? Am J Hematol. 2002; 71:139.